[go: up one dir, main page]

WO2024096692A1 - Composition pour améliorer l'état de la peau contenant une culture de cal de sambucus nigra ou un extrait de celui-ci en tant que principe actif - Google Patents

Composition pour améliorer l'état de la peau contenant une culture de cal de sambucus nigra ou un extrait de celui-ci en tant que principe actif Download PDF

Info

Publication number
WO2024096692A1
WO2024096692A1 PCT/KR2023/017563 KR2023017563W WO2024096692A1 WO 2024096692 A1 WO2024096692 A1 WO 2024096692A1 KR 2023017563 W KR2023017563 W KR 2023017563W WO 2024096692 A1 WO2024096692 A1 WO 2024096692A1
Authority
WO
WIPO (PCT)
Prior art keywords
elder
skin
extract
callus
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/017563
Other languages
English (en)
Korean (ko)
Inventor
선정윤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reblocell Co Ltd
Original Assignee
Reblocell Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reblocell Co Ltd filed Critical Reblocell Co Ltd
Priority to JP2025526226A priority Critical patent/JP2025539013A/ja
Publication of WO2024096692A1 publication Critical patent/WO2024096692A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04—Plant cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/82—Preparation or application process involves sonication or ultrasonication

Definitions

  • the present invention relates to a composition for improving skin condition containing elder callus culture or its extract as an active ingredient.
  • the skin which is the largest organ of the human body and takes up about 16% of the total human body volume, is composed of the epidermis layer, dermis layer, and subcutaneous fat layer. It is in direct contact with the external environment and is exposed to various factors such as temperature and humidity changes, ultraviolet rays, harmful microorganisms, and pollutants. It is an organ that acts as a primary defense shield that protects the body's organs from stimulation of the external environment and is also responsible for biochemical functions necessary for metabolism throughout the body.
  • the subcutaneous fat layer below the dermis is composed of adipocyte lobules and acts as a cushion to protect internal skin organs by preventing heat damage and absorbing shock from external environmental stimuli. It also contains nutrients such as triacylglycerol. It functions as a nutrient reservoir that is stored in the form of triacylglycerol and used as an energy source when needed.
  • nutrients such as triacylglycerol. It functions as a nutrient reservoir that is stored in the form of triacylglycerol and used as an energy source when needed.
  • collagen is a major component of the extracellular matrix, a major matrix protein produced by skin fibroblasts, and exists in the extracellular matrix. In addition, it is an important protein that accounts for about 30% of the total weight of biological proteins and has a sturdy triple helix structure. Collagen forms most of the organic matter of skin, tendons, bones, and teeth, and is especially high in bone and skin (dermis). Collagen also exists as fibrous inclusions in most other body structures. Collagen is a relatively weak immunogen, due to the shielding of potential antigenic determinants by the helical structure, and this helical structure also makes collagen resistant to protein degradation.
  • collagen The main functions of collagen are known to include mechanical rigidity of the skin, resistance of connective tissue, cohesion of tissues, support of cell adhesion, and induction of cell division and differentiation (during organism growth or wound healing) (Van der Rest et al. , Ann NY Acad Sci, 1990). This collagen decreases due to photoaging due to age and ultraviolet irradiation, and this is known to be closely related to the formation of wrinkles in the skin (Arthur KBalin et al, Aging and the skin, 1989). Collagen also plays an important role in wound healing, and by promoting collagen synthesis in damaged epithelium, wounds can be recovered quickly without scarring.
  • Plant elder ( Sambucus nigra ) is a general name for shrubs and their fruits belonging to the elderberry genus of the dicotyledonous marionette order Arboraceae. It grows in shady and humid areas of Europe, Asia, North Africa, and the North American continent and produces dark blue elderberries and creamy white elderflowers. It is a deciduous tree.
  • Elder plant ingredients are known to have antioxidant, anti-inflammatory, antiviral, skin immunity strengthening, skin trouble relieving, and skin soothing effects, making it a highly valuable species for use as a material for cosmeceuticals and bio-cosmetics.
  • 'callus' is a callus tissue that, when a plant is injured, cells regain their ability to divide, block the wound, and enlarge. It is formed by culturing tissue cut from the plant in a medium containing auxin. It refers to a special tissue mass, and interest in the use of callus has recently increased, and research is being conducted in various fields. If callus culture, which is a mass of undifferentiated cells, is used, it can be considered valuable as a cosmetic raw material with excellent physiological activity.
  • a naturally derived elder callus extract was developed from elder, a plant that is highly useful as a biomaterial, as an active ingredient that has excellent safety and has skin moisturizing, regenerative, and collagen decomposition effects.
  • this elder callus extract when used in combination with the growth factor EGF (Epidermal Growth Factor), had a synergistic effect on skin moisturization, regeneration, and inhibition of collagen decomposition compared to when used alone, and the present invention was completed. .
  • EGF Epimal Growth Factor
  • the present invention aims to solve the above-described problems and other problems associated therewith.
  • the purpose of the present invention is to provide a cosmetic composition for improving skin condition containing elder callus culture or its extract as an active ingredient.
  • Another object of the present invention is to provide a quasi-drug composition for preventing or improving skin diseases containing elder callus culture or its extract as an active ingredient.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin diseases containing elder callus culture or its extract as an active ingredient.
  • Another object of the present invention is to provide a method for producing a composition for improving skin condition containing elder callus culture or its extract.
  • Another object of the present invention is to provide a method of improving skin condition comprising applying a composition containing elder callus culture or an extract thereof as an active ingredient to the skin or mucous membrane of an individual.
  • Another object of the present invention is to provide a method for preventing or treating skin diseases comprising administering to an individual a composition containing an elder callus culture or an extract thereof as an active ingredient.
  • Another object of the present invention is to provide the use of a composition containing elder callus culture or its extract as an active ingredient for improving skin condition.
  • Another object of the present invention is to provide the use of a composition containing elder callus culture or its extract as an active ingredient for preventing or treating skin diseases.
  • Another object of the present invention is to provide the use of a composition containing elder callus culture or its extract as an active ingredient for the production of a drug for preventing or treating skin diseases.
  • the present invention provides a cosmetic composition for improving skin condition containing elder callus culture or its extract as an active ingredient.
  • 'Elder Sambucus nigra
  • 'Elder is a general name for shrubs and their fruits belonging to the Elderberry genus of the dicotyledonous Maderaceae family, and is a dark blue elderberry that grows in shady and humid areas of Europe, Asia, North Africa, and the North American continent. It is a deciduous tree with cream-white elderflowers. It grows in a variety of conditions, including moist or dry soil, mainly in sunny locations. Both the flowers and berries have long been used in cooking and are mainly used for cordials and wine.
  • 'callus' is a callus tissue that when a plant is wounded, the cells regain their ability to divide, block the wound, and enlarge.
  • the tissue cut from the plant is cultured in a medium containing auxin, or It refers to an undifferentiated tissue or cell mass that forms when a certain type of plant is wounded or the wounded area is treated with auxin, and can permanently divide and proliferate by subculturing in a new medium.
  • Such callus is an amorphous tissue or cell mass that has lost the ability to produce normal organ formation or tissue differentiation, and is mostly made up of podocytes. In a broad sense, it also includes plant tumor tissue caused by infection with Agrobacterium, etc.
  • 'callus' can be derived from any part of the plant elder, but in one embodiment, it is a stem, leaf, petal, sepal, fruit, ovary, part of placental tissue, or a germinated part of a seed.
  • the callus may be derived by cutting cotyledons from seedlings, and preferably may be derived from the leaves or stems of young elders.
  • 'callus culture' is callus cultured in a medium.
  • the above medium can be used without limitation as long as it is a medium commonly used for callus culture in the technical field.
  • the 'extract' is a liquid component obtained by immersing the desired material, such as an elder callus culture, in various solvents and then extracting it at room temperature or at a heated state for a certain period of time. Obtained by removing the solvent from the liquid component. It means the result of solid content, etc. In addition, it can be comprehensively interpreted to include all diluted solutions of the above results, concentrated solutions thereof, crude products, purified products, etc.
  • the extract can be obtained by extraction with water or various organic solvents, but is not particularly limited thereto, and is preferably extracted with water, alcohol with 1 to 4 carbon atoms, or a mixed solvent thereof.
  • the method for obtaining the extract is not particularly limited thereto, but is preferably a hydrothermal extraction method in which the dried product or processed product is immersed in the solvent and extracted at a temperature of 90 to 120 ° C., at a room temperature of 10 to 25 ° C. Methods such as cold needle extraction, heat extraction by heating to 40 to 100°C, ultrasonic extraction by applying ultrasonic waves, and reflux extraction using a reflux cooler can be used. Preferably, extraction is done using hot water extraction. You can.
  • the extraction solvent is preferably added in an amount of 1 to 20 times the weight for extraction, and the extraction temperature is preferably 90 to 120°C, but is not limited thereto. Additionally, the extraction time is preferably 1 to 4 hours, and extraction for 2 hours is most preferable, but is not limited thereto. Drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, and more preferably freeze drying, but is not limited to these.
  • the extracted liquid can be used directly or after being concentrated and/or dried.
  • organic solvents methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N,N-dimethylformamide (DMF), dimethyl sulfoxide
  • An organic solvent such as (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof can be used, and the active ingredients of the herbal medicine can be extracted at room temperature or by heating under conditions where the active ingredients are not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary depending on the organic solvent being extracted, so select and use an appropriate organic solvent.
  • the extract can be concentrated or diluted, a distillate of the extract can be used, or the extract can be freeze-dried again and used in powder form.
  • the 'skin condition improvement' may include, but is not limited to, skin regeneration, wrinkle improvement, skin aging prevention, skin elasticity maintenance, skin moisturization, or wound improvement.
  • the 'improvement' refers to all actions that improve or benefit the skin condition by using a composition containing the elder callus culture or extract thereof according to the present invention.
  • the term 'wrinkle improvement' in the present invention refers to maintaining or strengthening wrinkles and elasticity of the skin.
  • Collagen a collagen fiber in the dermal layer of the skin, and elastin, an elastic fiber, are the main proteins that play this role and control skin elasticity, so they have an inhibitory effect on the activity of elastase and/or collagenase that secrete them. In some cases, it can show a wrinkle improvement effect.
  • the term 'skin regeneration' in the present invention refers to the recovery process of skin tissue against damage caused by external and internal causes. Damage due to external causes may include ultraviolet rays, external contaminants, wounds, trauma, etc., and damage due to internal causes may include stress, etc., but are not limited thereto.
  • the term 'skin aging prevention' in the present invention refers to preventing chronological aging (intrinsic aging), which is natural aging that occurs due to physiological changes in the body over time, and photoaging (photogenic aging) that occurs in areas exposed to sunlight. or delaying anything.
  • chronological aging intrinsic aging
  • photoaging photogenic aging
  • skin aging not only must the skin be protected from external harmful environments, but the formation of wrinkles must be suppressed as much as possible by activating skin cells and promoting the synthesis of biosynthetic proteins such as collagen and elastin.
  • an elastic fiber form a network structure in the dermal layer.
  • Skin aging of the present invention may be photoaging caused by UV-B ultraviolet rays, but is not limited thereto.
  • photoaging of skin cells may occur due to light with a wavelength of 280 nm to 40 nm included in sunlight.
  • damage to skin or fibers may occur due to irradiation of ultraviolet rays such as UV-B, which has a wavelength in the range of 280 nm to 320 nm, and a blackening of the skin may occur.
  • UV-B When UV-B is irradiated, the accumulation of active oxygen (e.g. H 2 O 2 ) and free radicals within skin cells is promoted, and the radicals stimulate the intracellular signaling system to oxidize biomolecules such as DNA, proteins, and lipids.
  • active oxygen e.g. H 2 O 2
  • the improvement of the skin condition of the present invention may be due to cell proliferation promoting activity, and may specifically promote the proliferation of human keratinocytes or fibroblasts, but is not limited thereto.
  • the improvement of the skin condition of the present invention may be due to inhibition of collagen decomposition, but is not limited thereto, and preferably may be by inhibiting the activity of matrix metalloproteinases (MMPs), which are collagen decomposition enzymes, and may be specifically This reduces the expression of mRNA of matrix metalloproteinases 1 (MMP1), matrix metalloproteinases 2 (MMP2), or matrix metalloproteinases 9 (MMP9). It may be.
  • MMPs matrix metalloproteinases
  • composition of the present invention may increase the expression of hyaluronic acid synthase or aquaporin in keratinocytes, specifically, hyaluronic acid synthase 1 (HAS-1). , it may increase the mRNA expression of Hyaluronan synthase 2 (HAS-2), Hyaluronan synthase 3 (HAS-3), or Aquaporin 3 (AQP-3). there is.
  • HAS-1 hyaluronic acid synthase 1
  • HAS-2 Hyaluronan synthase 2
  • HAS-3 Hyaluronan synthase 3
  • AQP-3 Aquaporin 3
  • the term 'wound' in the present invention refers to a disruption in the normal continuity of the skin structure due to physical damage to the skin, specifically contusion or bruise, laceration, avulsion, and penetrating wound. (penetrated wound), non-healing traumatic wound, destruction of tissue by irradiation, abrasion, bone gangrene, gun-shot wound, cut, burn, frostbite, skin ulcer, dry skin, keratosis skin, Cracks, tears, dermatitis, pain due to dermatophytosis, wounds such as surgical wounds, vascular disease wounds, corneal wounds, bedsores, flat sores, conditions related to diabetes and poor circulation, chronic ulcers, suture sites after plastic surgery, spinal injury wounds , refers comprehensively to damage to parts of an entity, such as gynecological wounds, chemical wounds, and acne.
  • the term 'skin moisturizing' means increasing moisture in the skin and maintaining a moist state.
  • composition containing the elder callus extract of the present invention may not be cytotoxic to human keratinocytes or human fibroblasts.
  • the composition of the present invention may contain the elder callus culture or its extract in various amounts as long as it has effects such as wrinkle improvement, skin moisturization, skin regeneration, or wound improvement.
  • the elder callus culture or its extract The extract may be contained in an amount of 0.1 to 10% by weight based on the total weight of the composition. This ratio is only an exemplary range, and it is obvious to those skilled in the art that even if it is 20% or 30% or more, it has excellent effects such as improving skin condition, moisturizing skin, and improving skin wrinkles.
  • composition of the present invention may further contain epithelial growth factor (EGF), and when it contains the elder callus culture or its extract and EGF at the same time, it improves wrinkles, moisturizes the skin, and regenerates the skin. Alternatively, effects such as wound improvement may be further increased.
  • EGF epithelial growth factor
  • the epidermal growth factor is a polypeptide with a molecular weight of about 6Ka consisting of 53 amino acids and 3 disulfide bonds.
  • EGF is a growth factor that promotes cell growth, proliferation, and differentiation by specifically binding to the epidermal growth factor receptor (EGFR) present on the cell surface. It promotes cell proliferation of fibroblasts and helps repair damaged skin areas. It plays a key role in skin regeneration, including promoting angiogenesis, inducing the secretion of other regeneration promoting factors, and promoting the synthesis of fibronectin.
  • the cosmetic composition according to the present invention contains various ingredients commonly used in cosmetic compositions, such as water-soluble ingredients, powder ingredients, and oil, as necessary, within the range that does not reduce the effect of the present invention.
  • surfactants, moisturizers, viscosity modifiers, preservatives, antioxidants, fragrances, pigments, etc. may be combined.
  • Non-limiting examples of the surfactants that can be used include anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants. More specifically, the anionic surfactant includes alkylbenzene sulfonate, polyoxyalkylene alkyl sulfuric acid ester salt, alkyl sulfuric acid ester salt, olefin sulfonate, alkyl phosphate, polyoxyalkylene alkyl ether phosphate, and dialkyl sulfosuccine. Salts, fatty acid salts, etc.
  • nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyhydric alcohol fatty acid partial ester, polyoxyethylene polyhydric alcohol fatty acid partial ester, polyglycerol fatty acid ester, and polyoxyethylene fatty acid ester.
  • examples include ethylene hydrogenated castor oil derivatives and fatty acid diethanolamide.
  • cationic surfactants include tertiary aliphatic amine salts, alkyltrimethylammonium halides, dialkyldimethylammonium halides, etc.
  • amphoteric surfactants include amide betaine type, imidazolinium betaine type, and sulfobetaine type. etc. can be mentioned.
  • Examples of the moisturizing agent include glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol, and sorbitol.
  • Examples of the preservative include benzoic acid, dehydroacetic acid, paraoxybenzoic acid ester (methyl paraoxybenzoate, butyl paraoxybenzoate, etc.), phenoxyethanol, etc.
  • the antioxidants include ascorbic acid, BHA, etc., and in addition, ultraviolet absorbers, anti-inflammatory agents, fresheners, etc. can be added.
  • the cosmetic composition of the present invention includes solution, external ointment, cream, foam, nutritional lotion, softening lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid cleanser, bath agent, sunscreen cream, sun oil, suspension, and emulsion. It can be prepared in a formulation selected from the group consisting of liquid, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray. no.
  • the cosmetic composition of the present invention may further include one or more carriers acceptable in cosmetic formulations, and common ingredients include, for example, oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, Preservatives, fragrances, etc. may be appropriately mixed, but are not limited thereto.
  • 'acceptable carrier in cosmetic preparations means a compound or composition that is already known and used or a compound or composition that will be developed in the future that can be included in cosmetic preparations and has no toxicity, instability or irritation beyond what the human body can adapt to when contacted with the skin. It says something that doesn't exist.
  • the carrier may be included in the composition of the present invention in an amount of about 1% by weight to about 99.99% by weight based on the total weight thereof, preferably about 90% by weight to about 99.99% by weight of the weight of the composition.
  • the ratio varies depending on the formulation in which the composition of the present invention is manufactured, its specific application area (face, neck, etc.), and its preferred application amount, the ratio does not limit the scope of the present invention in any respect. It should not be understood as
  • acceptable carriers vary depending on the formulation of the cosmetic composition.
  • the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. are used as carrier ingredients. may be used, but is not limited thereto. These may be used alone or in combination of two or more types.
  • lactose, talc, silica, aluminum hydroxide, calcium silcate, polyamide powder, etc. may be used as carrier ingredients, and especially in the case of a spray, chlorofluorohydride may be additionally used. It may include propellants such as locarbon, propane/butane, or dimethyl ether, but is not limited thereto, and these may be used alone or in a mixture of two or more types.
  • a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, etc. can be used, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. may be used, but is not limited thereto, and may be used alone or in a mixture of two or more types.
  • the carrier components include water, liquid diluents such as ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, and miso.
  • Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but are not limited thereto, and they may be used alone or in a mixture of two or more types.
  • alkali metal salts of fatty acids alkali metal salts of fatty acids, hemiester salts of fatty acids, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. are used as carrier components. It may be, but is not limited to, these may be used alone or in combination of two or more types.
  • the present invention provides a quasi-drug composition for preventing or improving skin diseases containing elder callus culture or an extract thereof as an active ingredient.
  • 'skin disease' of the present invention may be selected from the group consisting of skin wounds, skin scars, and skin pigmentation, but is not limited thereto.
  • Non-limiting examples of the terms 'skin wound' and 'skin scar' of the present invention include abrasions, scars caused by abrasions, etc.
  • the term 'skin pigmentation' of the present invention refers to all diseases caused by skin pigmentation due to increased production of melanin.
  • Non-limiting examples of the skin pigmentation disease include melasma, freckles, spots, solar pigmentation, pigmentation after drug use, pigmentation after inflammation, and pregnancy-related pigmentation.
  • the term 'prevention' of the present invention refers to any act of suppressing or delaying skin diseases such as skin wounds, skin scars, and skin pigmentation by administering or applying the elder callus culture or extract thereof of the present invention to an individual.
  • the term 'improvement' of the present invention refers to any act of alleviating the symptoms of skin diseases such as skin wounds, skin scars, and skin pigmentation by administering or applying the elder callus culture or extract thereof of the present invention to an individual.
  • 'quasi-drugs' are articles used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases in humans or animals, but are not instruments, machines, or devices, and are not intended to have a pharmacological effect on the structure and function of humans or animals. It refers to products used for the purpose, excluding those that are not instruments, machines, or devices.
  • One specific example may include preparations for internal use, but is not limited thereto, and the formulation method, dosage, usage method, and components of quasi-drugs etc. can be appropriately selected from conventional techniques known in the technical field.
  • the quasi-drug composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents as needed.
  • the pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effect of the present invention, and includes, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. It can be included.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases containing elder callus culture or an extract thereof as an active ingredient.
  • the ‘elder’, ‘callus’, ‘callus culture’, ‘extract’, ‘skin disease’, ‘prevention’ and ‘composition’ are as described above.
  • the 'treatment' refers to any act of administering or applying the elder callus culture or extract thereof of the present invention to an individual to improve, alleviate, or benefit skin diseases such as skin wounds, skin scars, and skin pigmentation. means.
  • composition of the present invention may further include a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers may further include, for example, a carrier for oral administration or a carrier for parenteral administration.
  • Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc.
  • Carriers for parenteral administration may also include water, suitable oils, saline solutions, aqueous glucose and glycols, and the like. Additionally, stabilizers and preservatives may be additionally included. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • the pharmaceutical composition of the present invention can be administered to mammals, including humans, by any method.
  • it can be administered orally or parenterally, and parenteral administration methods include intravenous, intramuscular, intraarterial, intracentral, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, and intranasal.
  • parenteral administration methods include intravenous, intramuscular, intraarterial, intracentral, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, and intranasal.
  • the pharmaceutical composition of the present invention can be formulated into a preparation for oral administration or parenteral administration according to the administration route described above.
  • one or more buffers e.g. saline or phosphate buffered saline (PBS)
  • antioxidants e.g. saline or phosphate buffered saline (PBS)
  • bacteriostatic agents e.g. EDTA or glutathione
  • fillers e.g. EDTA or glutathione
  • extenders binders
  • adjuvants e.g. For example, aluminum hydroxide
  • suspending agents thickening agents, wetting agents, disintegrating agents, surfactants, diluents or excipients
  • surfactants diluents or excipients
  • Solid preparations for oral administration include tablets, pills, powders, granules, solutions, gels, syrups, slurries, suspensions or capsules, etc.
  • These solid preparations include the pharmaceutical composition of the present invention and at least one excipient, e.g.
  • starch including corn starch, wheat starch, rice starch, potato starch, etc.
  • calcium carbonate sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol and maltitol.
  • It can be prepared by mixing cellulose, methyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl-cellulose, or gelatin.
  • tablets or dragees can be obtained by combining the active ingredient with solid excipients, grinding them, adding suitable auxiliaries, and processing them into a granule mixture.
  • lubricants such as magnesium styrate talc are also used.
  • Liquid preparations for oral use include suspensions, oral solutions, emulsions, or syrups.
  • various excipients such as wetting agents, sweeteners, fragrances, or preservatives may be included.
  • cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant, and anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives may be additionally included. .
  • the pharmaceutical composition of the present invention can be formulated with a suitable parenteral carrier in the form of injections, transdermal administration, and nasal inhalation according to methods known in the art.
  • a suitable parenteral carrier in the form of injections, transdermal administration, and nasal inhalation according to methods known in the art.
  • the above injections must be sterilized and protected from contamination by microorganisms such as bacteria and fungi.
  • suitable carriers may be, but are limited to, solvents or dispersions including water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), mixtures thereof, and/or vegetable oils. That is not the case.
  • suitable carriers include Hanks' solution, Ringer's solution, PBS containing triethanolamine, or isotonic solutions such as sterile water for injection, 10% ethanol, 40% propylene glycol, and 5% dextrose. .
  • it may additionally contain various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.
  • the injection may additionally contain an isotonic agent such as sugar or sodium chloride.
  • transdermal administration forms such as ointments, creams, lotions, gels, external solutions, paste preparations, linear preparations, and aerol preparations are included.
  • 'transdermal administration means administering a pharmaceutical composition topically to the skin so that an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin.
  • compositions used according to the invention may be packaged in pressurized packs or using a suitable propellant, such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. It can be conveniently delivered in the form of an aerosol spray from a nebulizer.
  • the dosage unit can be determined by providing a valve that delivers a metered amount.
  • gelatin capsules and cartridges for use in inhalers or insufflators can be formulated to contain a powder mixture of the compound and a suitable powder base such as lactose or starch.
  • Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975 Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a text generally known in all pharmaceutical chemistry.
  • the amount of the active compound in the unit dose formulation may vary, and specifically, it may be adjusted to about 0.01 mg to about 1 g per time based on an average human weighing 70 kg.
  • the administered dose may vary depending on the requirements of humans and mammals, the severity of the disease being treated, and the final composition of the compound used. It falls to those skilled in the art to determine the appropriate dosage for a particular situation.
  • composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, or methods using biological response modifiers.
  • the present invention includes the steps of (a) producing an elder callus culture by inducing and culturing elder callus from an elder plant tissue; (b) preparing an elder callus extract from the elder callus culture; and (c) producing a composition containing the elder callus culture or extract thereof.
  • the elder plant tissue may be a part of the stem, leaf, petal, sepal, fruit, ovary, or placenta tissue, but is not limited thereto, and preferably leaves or stem of a young elder are collected. You can get it by doing this.
  • step (a) may include collecting elder plant tissue and sterilizing it, and the sterilization may be used without limitation if there is a sterilization method commonly used in the callus induction process in the same technical field. It is possible, but specifically, the elder plant tissue is collected, washed in running water, sterilized with 70% ethanol (EtOH) solution for 30 to 60 seconds, and then 2% sodium hypochlorite with a small amount of Tween20 added. It may be sterilized by immersing in the solution for 3 to 7 minutes.
  • EtOH 70% ethanol
  • step (a) may be inducing elder callus in a medium containing picloram, 1-Naphthaleneacetic acid, or 6-Benzylaminopurine, , preferably a medium containing 1 to 20 ⁇ M of 1-naphthalene acetic acid and 0.1 to 1 ⁇ M of 6-benzylaminopurine, or a medium containing 1 to 20 ⁇ M of picloram and 0.1 to 1 ⁇ M of 6-benzylaminopurine, It is not limited to this.
  • step (a) may include culturing the elder callus in a solid medium and then additionally culturing it in a liquid medium.
  • the elder callus induced in step (a) can be selected and stabilized as good callus on solid medium, and then 0.1 to 1 ⁇ M of 6-Benzylaminopurine and picloram are added to grow the callus.
  • (Picloram) may include culturing using a medium containing 1 to 20 ⁇ M. Thereafter, it may include the step of culturing in a liquid medium to mass-cultivate the elder callus obtained by growing on a solid medium. The liquid medium is placed in a 500 ml Erlenmeyer flask, the elder callus in the cultured solid culture medium is inoculated, and the culture is repeated. This may include culturing a sufficient amount of callus.
  • an appropriate medium can be selected to specifically induce and culture elder callus. If there is a medium commonly used for plant tissue culture in the technical field, it can be used without restrictions.
  • MS medium, B5 medium, etc. are generally used.
  • the composition of MS medium (based on 1L) is 0.025 mg of CoCl 2.6H 2 O, 0.025 mg of CuSO 4.5H 2 O, 36.70 mg of FeNaEDTA, H 3 BO 3 6.20 mg, KI 0.83 mg, MnSO 4 .H 2 O 16.90 mg, Na 2 MoO 4 .2H 2 O 0.25 mg, ZnSO 4 .7H 2 O 8.60 mg, CaCl 2 332.02 mg, KH 2 PO 4 170.00
  • MS medium with a composition of 1900.00 mg, KNO 3 1900.00 mg, MgSO 4 180.54 mg, and NH 4 NO 3 1650.00 mg can be used.
  • the medium may contain zeatin, sucrose, agar, etc.
  • step (b) may include drying the elder callus culture obtained in step (a) to prepare a dried elder callus product, and mixing the dried product with purified water to prepare an extract.
  • a composition containing the elder callus culture obtained through the culture in step (a) is prepared as a composition in an appropriate form, or in the form of an extract through step (b). It can be obtained and manufactured into a composition of an appropriate form.
  • step (c) depending on the purpose, a composition of an appropriate form can be prepared by the known methods mentioned above.
  • the present invention provides a method for improving skin condition, comprising applying a composition containing elder callus culture or an extract thereof as an active ingredient to the skin or mucous membrane of an individual.
  • the present invention provides a method for preventing or treating skin diseases, comprising administering to an individual a composition containing an elder callus culture or an extract thereof as an active ingredient.
  • the subject may be a mammal, specifically a human, cow, sheep, goat, horse, pig, dog, cat, rabbit, rat, mouse, fish, bird, etc., but is not limited thereto.
  • the use of a composition containing elder callus culture or its extract as an active ingredient for improving skin condition is provided.
  • composition containing elder callus culture or its extract as an active ingredient for preventing or treating skin diseases is provided.
  • the present invention provides the use of a composition containing elder callus culture or its extract as an active ingredient for the production of a drug for preventing or treating skin diseases.
  • Elder callus culture or extract thereof according to the present invention inhibits collagen decomposition or promotes cell proliferation, has effects such as skin regeneration, maintaining skin elasticity, skin moisturizing, and improving skin wrinkles, and can be used in combination with epithelial cell growth factors. It has a greater synergistic effect when processed, so it can be used as a material for cosmetics and medicine.
  • Figure 1 shows the appearance of induced elder callus after stabilization after going through a good callus selection process on solid medium.
  • Figure 2 shows the results of confirming the cytotoxicity and cell proliferation effect of the elder callus extract on human keratinocytes.
  • Figure 3 shows the results of comparing the cytotoxicity and cell proliferation effects of EGF on human keratinocytes.
  • Figure 4 shows the results of confirming the cytotoxicity and cell proliferation effect of the elder callus extract on human fibroblasts.
  • Figure 5 shows the results of confirming the presence or absence of cytotoxicity and cell proliferation effect on human keratinocytes when combined treatment of elder callus extract and epidermal growth factor (EGF).
  • Figure 6 shows the results of confirming the presence or absence of cytotoxicity and cell proliferation effect on human fibroblasts when combined treatment of elder callus extract and epidermal growth factor (EGF).
  • Figure 7 shows the results of confirming the skin regenerative ability of human keratinocytes when treated with elder callus extract alone or in combination with elder callus extract and epidermal growth factor (EGF).
  • Figure 8 shows the results of confirming the mRNA expression level of matrix metalloproteinases (MMPs) in human fibroblasts when treated alone with elder callus extract or in combination with elder callus extract and epidermal growth factor (EGF). .
  • MMPs matrix metalloproteinases
  • Figure 9 shows the skin moisturizing factors hyaluronic acid synthase (HAS) and aquaporin (Aquaporin; This is the result of confirming the mRNA expression level of AQP).
  • HAS hyaluronic acid synthase
  • Amporin aquaporin
  • Elder plant tissues such as young elder leaves and stems were collected, washed in running water, sterilized for 60 seconds using a 70% ethanol (Merck, cat.603-002-00-5) solution, and then 2% sodium hypochlorite (Sodium hypochlorite). hypochlorite (Duksan, cat. 7681-52-9) solution for 7 minutes to sterilize.
  • the sterilized elder plant tissue was washed five times with sterilized distilled water to remove all remaining sterilizing solution.
  • Elder callus was induced using sterilized tissues as follows.
  • the disinfected and washed tissue samples were each cut to a certain size and wounded, placed on callus induction medium, and cultured in the dark at a temperature range of 26 to 28°C.
  • Picloram Duchefa, Cat. P0914.0005
  • 6-Benzylaminopurine BA
  • basic MS medium Merashige and Skoog, Duchefa Cat. M0222.0050
  • NAA 1-Naphthaleneacetic acid
  • the induced elder callus was stabilized after a good callus selection process on solid medium ( Figure 1). Then, to grow elder callus, the basic MS medium was cultured using a medium containing 1 and 10 ⁇ M of 6-benzylaminopurine (BA) and picloram, respectively, which are mainly used for plant callus growth.
  • BA 6-benzylaminopurine
  • picloram picloram
  • the culture was switched to a liquid medium culture stage.
  • 100 ml of liquid medium was placed in a 500 ml Erlenmeyer flask, inoculated with 3 well-cultured solid culture plates (plates) of elder callus, and cultured at 25°C and 100 rpm. This was cultured repeatedly to increase the amount of callus and secure a sufficient amount of callus.
  • An elder callus extract was prepared from an elder callus culture obtained in liquid culture.
  • the elder callus culture was washed five times with purified water and then freeze-dried at -80°C to obtain dried elder callus.
  • Elder callus extract was produced by placing 5 g of freeze-dried elder callus in 2 L of purified water and performing hot water extraction at 100°C for 2 hours. For experiments with accurate concentrations, the extract was freeze-dried again to prepare callus extract powder.
  • the keratinocyte cell line HaCaT a human skin cell
  • the degree of culture was equivalent to 85 to 90% of the area of the culture vessel, cells were detached by trypsin treatment, counted, and then subcultured at 5 ⁇ 10 3 cells/cm 2 .
  • DMEM Delbecco's Modified Eagle Medium, GIBCO
  • FBS fetal bovine serum
  • streptomycin 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin was used to culture the cells.
  • elder callus extract of the present invention can show improvement effects without skin irritation even when used for a long period of time.
  • the concentration of elder flower extract to be used as an experimental group to compare the effects of elder callus extract and epidermal growth factor (EGF) to be used when combined with elder extract elder flower extract and EGF were used. Cytotoxicity to human keratinocytes was also tested.
  • Human keratinocytes were counted and dispensed into a 24 well plate at 5 ⁇ 10 3 cells/well using a hemacytometer. When cultured in DMEM containing 10% FBS for 48 hours and reached ⁇ 50% of the surface area of the culture vessel, it was replaced with FBS-free DMEM containing elder callus extract or elder flower extract and cultured for an additional 24 hours. After incubation, 50 ⁇ l of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, SigmaM5655) solution (2.5 mg/ml) was added and cultured for an additional 3 hours.
  • MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
  • DMSO dimethyl sulfoxide
  • the elder callus extract of the present invention was not cytotoxic to human keratinocytes at all test concentrations.
  • callus was derived from elder and elder callus extract was used, a significantly better cell proliferation effect was observed compared to elder flower extract ( Figure 2).
  • EGF to be used in combination treatment does not show cytotoxicity to human keratinocytes at an EGF treatment concentration of 0.01 to 1 ppm, and in particular, shows a cell proliferation effect compared to the untreated group at 0.5 ppm ( Figure 3) .
  • the elder callus extract of the present invention does not cause skin irritation due to cytotoxicity even when used for a long period of time, and at the same time shows an effect of inducing the proliferation of human keratinocytes compared to the elder flower extract.
  • human fibroblasts CCD-986sk Prior to the safety test, human fibroblasts CCD-986sk were first cultured in an incubator at 37°C and 5% CO 2 . When the degree of culture was 85 to 90% of the area of the culture vessel, the cells were detached and counted by trypsin treatment, and then subcultured at 5 ⁇ 10 3 cells/cm 2 .
  • DMEM Delbecco's Modified Eagle Medium, GIBCO
  • FBS GIBCO
  • streptomycin 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin was used to culture the cells.
  • CCD-986sk was counted in a 24 well plate at 5 ⁇ 10 3 cells/well using a hemacytometer, and then aliquoted and cultured.
  • DMEM fetal bovine serum
  • FBS-free DMEM containing elder callus extract or elder flower extract
  • 50 ⁇ l of 2.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma M5655, USA) solution was added and cultured for an additional 3 hours.
  • DMSO dimethyl sulfoxide
  • ELISA Immunosorbent Assay
  • the elder callus extract of the present invention is not cytotoxic to human fibroblasts and shows a more excellent effect than the proliferation effect on human fibroblasts when treated with the elder flower extract (FIG. 4).
  • the concentration when treating elder flower extract or elder callus extract in combination with EGF was selected at a concentration that could compare the synergistic effect without affecting the experiment. Therefore, the elder flower extract or elder callus extract was set at 500 ppm, and EGF was set at 0.5 ppm.
  • the mixture of elder callus extract and epidermal growth factor (EGF) of the present invention was evaluated for the degree of cytotoxicity and cell proliferation on human keratinocytes and human fibroblasts.
  • the test method for human keratinocytes was performed in the same manner as Example 2, and the test method for human fibroblasts was performed in the same manner as Example 3.
  • the degree of wound regeneration was investigated as one of the main physiological activity mechanisms of cosmetic compositions for skin regeneration and skin soothing.
  • the skin regenerative activity of the elder callus extract and the elder callus extract and EGF mixture of the present invention was evaluated as follows.
  • HaCaT a keratinocyte cell line
  • a cell-free zone was formed in each well using a wound marker.
  • each well was washed three times with 1 ml of phosphate buffer (pH 7.4), and 3 ml of elder callus extract, elder flower extract, EGF, and extract and EGF mixture diluted with FBS-free DMEM culture medium were added to each well, and then CO 2 Cultured in an incubator for 24 hours.
  • the regenerative capacity (healing capacity) of elder callus extract, elder flower extract, EGF, and extract and EGF mixture was measured by setting the control group treated with only FBS-free DMEM medium without extract as 100. Regenerative capacity was measured by comparing the wound area with the untreated group through a microscope after staining the cells.
  • the elder callus extract of the present invention showed a skin regeneration effect in human keratinocytes compared to the untreated group.
  • the skin regeneration ability of human keratinocytes was confirmed by mixing elder callus extract and EGF, the skin regeneration ability was found to be significantly superior compared to when each sample was treated alone or with a combination of elder flower extract and EGF. was confirmed (Figure 7).
  • human fibroblasts were first cultured. CCD-986sk human dermal fibroblast cells are distributed at 2 ⁇ 10 4 cells/well in a 6 well plate and cultured in DMEM medium containing 10% FBS to ⁇ 70% of the surface area of the culture vessel, then diluted with FBS-free DMEM. Elder callus extract, elder flower extract, EGF, and the extract and EGF were treated in each well.
  • 5X prime script RT master mix (Takara, Japan) was added to the extracted RNA, reacted at 37°C for 15 minutes, synthesized into cDNA, and then RT-PCR was performed.
  • RT-PCR For RT-PCR, 2 ⁇ l of each primer was added to 1 ⁇ l of synthesized cDNA, 25 ⁇ l of EmeraldAmp GT PCR Master Mix (Takara, Japan) and 20 ⁇ l of tertiary sterilized water were added and mixed well. Denaturation was performed at 95°C for 30 seconds, extension was performed at 72°C for 1 minute, a total of 30 cycles, and annealing temperature was performed at the optimal temperature for each primer.
  • the MMP degrading enzymes identified in this experiment are MMP1, MMP2, and MMP9.
  • the primer sequences of the MMPs used are listed in Table 2.
  • the PCR product was electrophoresed on a 1.2% agarose gel, and then it was confirmed that there was no primer dimer and that the size of the PCR product was correct.
  • the amount of product was quantitatively analyzed according to band concentration using the Image J program (National Institute of Health, USA).
  • MMPs collagen-degrading enzymes
  • the MMP2 mRNA expression level was particularly decreased in the elder callus extract treated group compared to the untreated group, and also the elder callus extract and EGF each
  • the mRNA expression levels of MMPs were decreased in human fibroblasts when treated with mixed substances compared to single substances. It was confirmed that the synergistic effect on inhibiting collagen decomposition was superior even when compared to treatment with a mixture of elder flower extract and EGF (FIG. 8).
  • the mixture of elder callus extract and EGF of the present invention can inhibit collagenase in human fibroblasts and thereby have a wrinkle prevention effect.
  • HAS hyaluronic acid synthase
  • AQP aquaporin
  • 5X prime script RT master mix (Takara, Japan) was added to the extracted RNA, reacted at 37°C for 15 minutes, synthesized into cDNA, and then RT-PCR was performed.
  • RT-PCR For RT-PCR, 2 ⁇ l of each primer was added to 1 ⁇ l of synthesized cDNA, 25 ⁇ l of EmeraldAmp GT PCR Master Mix (Takara, Japan) and 20 ⁇ l of tertiary sterilized water were added and mixed well. Denaturation was performed at 95°C for 30 seconds, extension was performed at 72°C for 1 minute, a total of 30 cycles, and annealing temperature was performed at the optimal temperature for each primer.
  • the primer sequences of GAPDH (Glyceraldehyde-3-phosphate dehydrogenase), HAS-1, 2, 3, and AQP-3 used in this test are shown in Table 3.
  • the PCR product was checked on a 1.2% agarose gel to ensure that there were no non-specific PCR products or primer dimers, and the amount of the product was measured using the Image J program (National Institute of Health, USA). Quantitative analysis was performed according to band concentration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition permettant d'améliorer l'état de la peau, contenant une culture de cal de Sambucus nigra ou un extrait de celui-ci en tant que principe actif. La culture de cal de Sambucus nigra ou un extrait de celui-ci selon la présente invention inhibe la décomposition du collagène ou favorise la prolifération cellulaire, présent des effets tels que la régénération de la peau, le maintien de l'élasticité de la peau, l'hydratation de la peau et la réduction des rides de la peau, et présente un effet synergique plus grand lorsqu'il est traité en combinaison avec le facteur de croissance des cellules épithéliales, et peut ainsi être utilisé en tant que matériau pour des produits cosmétiques, des médicaments et analogues.
PCT/KR2023/017563 2022-11-04 2023-11-03 Composition pour améliorer l'état de la peau contenant une culture de cal de sambucus nigra ou un extrait de celui-ci en tant que principe actif Ceased WO2024096692A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025526226A JP2025539013A (ja) 2022-11-04 2023-11-03 エルダーカルス培養物又はその抽出物を有効成分として含有する皮膚状態改善用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220146025 2022-11-04
KR10-2022-0146025 2022-11-04

Publications (1)

Publication Number Publication Date
WO2024096692A1 true WO2024096692A1 (fr) 2024-05-10

Family

ID=90931042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/017563 Ceased WO2024096692A1 (fr) 2022-11-04 2023-11-03 Composition pour améliorer l'état de la peau contenant une culture de cal de sambucus nigra ou un extrait de celui-ci en tant que principe actif

Country Status (3)

Country Link
JP (1) JP2025539013A (fr)
KR (1) KR102701610B1 (fr)
WO (1) WO2024096692A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118806670A (zh) * 2024-09-19 2024-10-22 广州优科生物科技有限公司 一种植物愈伤组织提取物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
KR101607503B1 (ko) * 2015-08-04 2016-03-30 주식회사 유니솔브 아이스플랜트 캘러스 추출물을 유효성분으로 포함하는 항산화, 미백 및 주름 개선을 위한 조성물
KR20160037365A (ko) * 2014-09-26 2016-04-06 주식회사 엘지생활건강 엘더꽃 추출물을 포함하는 피부 보습용 화장료 조성물
KR102348419B1 (ko) * 2021-06-25 2022-01-10 주식회사 참존 사과, 딸기 및 엘더베리 혼합발효추출물을 유효성분으로 함유하는 화장료 조성물
KR20220008484A (ko) * 2020-07-14 2022-01-21 주식회사 코리아나화장품 햄프씨드오일, 식물캘러스배양여과물 및 펩타이드를 유효성분으로 함유하는 피부 상태 개선용 화장료 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101969475B1 (ko) 2017-10-23 2019-04-16 (주)태일 엉겅퀴를 포함하는 복합 식물의 추출물을 유효성분으로 포함하는 피부개선용 화장료 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
KR20160037365A (ko) * 2014-09-26 2016-04-06 주식회사 엘지생활건강 엘더꽃 추출물을 포함하는 피부 보습용 화장료 조성물
KR101607503B1 (ko) * 2015-08-04 2016-03-30 주식회사 유니솔브 아이스플랜트 캘러스 추출물을 유효성분으로 포함하는 항산화, 미백 및 주름 개선을 위한 조성물
KR20220008484A (ko) * 2020-07-14 2022-01-21 주식회사 코리아나화장품 햄프씨드오일, 식물캘러스배양여과물 및 펩타이드를 유효성분으로 함유하는 피부 상태 개선용 화장료 조성물
KR102348419B1 (ko) * 2021-06-25 2022-01-10 주식회사 참존 사과, 딸기 및 엘더베리 혼합발효추출물을 유효성분으로 함유하는 화장료 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118806670A (zh) * 2024-09-19 2024-10-22 广州优科生物科技有限公司 一种植物愈伤组织提取物及其制备方法和应用

Also Published As

Publication number Publication date
KR20240069622A (ko) 2024-05-20
KR102701610B1 (ko) 2024-09-05
JP2025539013A (ja) 2025-12-03

Similar Documents

Publication Publication Date Title
KR102298371B1 (ko) 명월초 캘러스 유래 pdrn을 유효성분으로 포함하는 피부 상태 개선용 조성물 및 그 제조방법
WO2021033829A1 (fr) Peptide ayant une activité d'amélioration de l'état de la peau et son utilisation
WO2019045259A2 (fr) Composition cosmétique comprenant un extrait de fleur de dendrobium candidum wallich ex lindley
KR20160043551A (ko) 에델바이스 식물 세포 배양 추출물을 함유한 항염 및 항노화 효과를 지닌 피부 외용제 조성물 및 그 제조방법
WO2024150983A1 (fr) Composition cosmétique pour l'amélioration de la peau comprenant un extrait de cannabis sativa l. en tant que principe actif
WO2015156439A1 (fr) Composition pour améliorer l'état de la peau, comprenant un extrait d'andrographis paniculata, un andrographolide ou sel correspondant
WO2020004745A1 (fr) Micro-aiguille revêtue d'un médicament et son procédé de fabrication
WO2024049120A1 (fr) Composition cosmétique contenant un extrait extrait au moyen d'un solvant eutectique naturel respectueux de l'environnement
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
WO2020071630A1 (fr) Composition pour améliorer la peau comprenant des extraits de produits naturels
WO2024096692A1 (fr) Composition pour améliorer l'état de la peau contenant une culture de cal de sambucus nigra ou un extrait de celui-ci en tant que principe actif
WO2017200288A1 (fr) Composition pour le blanchiment de la peau, la prévention du vieillissement de la peau ou l'amélioration des rides de la peau, comprenant un extrait médicinal oriental naturel en tant que substance active
WO2021251790A1 (fr) Conjugué acide désoxycholique-peptide à activité anti-obésité et son utilisation
WO2020138674A1 (fr) Composition pour la relaxation musculaire
WO2017119756A1 (fr) Nouveau peptide fonctionnel anti-inflammatoire, blanchissant la peau, anti-âge et atténuant les rides, et composition contenant le peptide
KR101693923B1 (ko) 잘피 식물 세포 배양 추출물을 함유한 항염 및 항노화 효과를 지닌 피부 외용제 조성물 및 그 제조방법
WO2025143444A1 (fr) Composition comprenant un exosome dérivé de camellia japonica callus en tant que principe actif pour améliorer l'état de la peau
WO2019139403A1 (fr) Composition contenant de la séricine, un extrait de torilis japonica et un extrait de viscum album pour la régénération de la peau, l'apaisement de la peau ou la cicatrisation des plaies
WO2019132217A1 (fr) Composition cosmétique comprenant comme principe actif une solution fermentée du fruit de styphnolobium japonicum ou un extrait liquide de celle-ci et destinée à réduire les rides de la peau, et procédé de préparation associé
WO2023219300A1 (fr) Nouvelle souche de chlorella vulgaris et son utilisation
WO2023127986A1 (fr) Peptide ayant une activité d'amélioration de l'état de la peau et utilisation de celui-ci
WO2021251730A1 (fr) Composition comprenant de la regentide-034 et de la regentide-041 pour le soin de la peau ou la réduction des rides
WO2024122713A1 (fr) Peptide présentant une activité d'amélioration de l'état de la peau et son utilisation
WO2019039630A1 (fr) Peptide bioactif dérivé de follistatine et son utilisation
WO2018151563A1 (fr) Composition pour prévenir le photovieillissement et soulager les rides de la peau, contenant un extrait de cosmos bipinnatus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23886386

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025526226

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025526226

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23886386

Country of ref document: EP

Kind code of ref document: A1